The innovative work of Canada’s isotope supply chain is revolutionizing the production of emerging isotopes like Actinium-225. Ac-225 offers significant benefits to patients, including effective, non-invasive treatments for a variety of cancers.
This event will profile Ac-225 as an emerging medical isotope with promising results in oncology using Targeted Alpha Therapy (TaT). Speakers will discuss its uses, production methods, challenges in its supply chain, and benefits of TaT for patients. The event will also profile a new key player in the production of Ac-225, Actineer, the new joint venture between Canadian Nuclear Laboratories and ITM Isotope Technologies Munich.
Through discussions of how Actineer is innovating to produce Ac-225 at a commercial scale, this event aims to celebrate Canadian leadership in the production of this rare isotope, while emphasizing how Ac-225 and TaT can revolutionize the standard of cancer treatment.
Speakers:
Carolina de Aguiar Ferreira - Assistant Professor of Radiology, Pharmacology & Toxicology and Biomedical Engineering at Michigan State University
Mike Sathegke - Head of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, South Africa
Ram Mullur, President of Actineer
Moderator: Melody Greaves, Manager of Strategic Initiatives, Canadian Nuclear Isotope Council
Disclaimer: This webinar is hosted in Canada by a Canadian company and will be held in compliance with Canadian legal and regulatory requirements.
